Video Experimental Relacionado
Updated: Jul 23, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
HMG CoA inhibidor de la reductasa (estatin) y el calcio de la válvula aórtica
David M Shavelle1, Junichuro Takasu, Matthew J Budoff
1Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98195-6422, USA.
Lancet (London, England)
|April 12, 2002
Resumen
Las estatinas pueden retrasar la progresión de la acumulación de calcio de la válvula aórtica (AVC) en pacientes con enfermedad valvular aórtica calcificada. Este estudio encontró que el uso de estatinas se asoció con tasas de acumulación y progresión de AVC significativamente reducidas.
Área de la Ciencia:
- Cardiología Cardiología.
- Farmacología Farmacología.
- Radiología Radiología.
Sus antecedentes:
- La esclerosis valvular aórtica calcificada / estenosis carece de tratamiento farmacológico.
- La calcificación de la válvula aórtica está relacionada con la deposición de lipoproteínas.
Objetivo del estudio:
- Para investigar el potencial de los inhibidores de la reductasa (estatinas) de la 3-hidroxi-3-metilglutaril-coenzima A (HMG COA) en la reducción de la acumulación de calcio en la válvula aórtica (AVC).
Principales métodos:
- Análisis retrospectivo de 65 pacientes sometidos a dos tomografías computarizadas con haz de electrones.
- Comparación de las tasas de acumulación de AVC entre los pacientes que toman estatinas y los que no.
Principales resultados:
- Los pacientes en estatinas mostraron una tasa mediana de acumulación de AVC 62-63% más baja (p=0.006).
- Un 44-49% menos de pacientes en estatinas tenían una progresión definitiva del AVC (p=0,043).
Conclusiones:
- Las estatinas pueden representar una estrategia terapéutica potencial para disminuir la acumulación de AVC.
- Se necesita más investigación para confirmar la eficacia de las estatinas en el tratamiento de la enfermedad de la válvula aórtica calcifica.
Videos de Conceptos Relacionados
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...